These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 12569553)
1. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. Yip YL; Novotny J; Edwards M; Ward RL Int J Cancer; 2003 Apr; 104(3):303-9. PubMed ID: 12569553 [TBL] [Abstract][Full Text] [Related]
2. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. Yip YL; Smith G; Koch J; Dübel S; Ward RL J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813 [TBL] [Abstract][Full Text] [Related]
3. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085 [TBL] [Abstract][Full Text] [Related]
4. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426 [TBL] [Abstract][Full Text] [Related]
5. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Klinger M; Farhan H; Just H; Drobny H; Himmler G; Loibner H; Mudde GC; Freissmuth M; Sexl V Cancer Res; 2004 Feb; 64(3):1087-93. PubMed ID: 14871842 [TBL] [Abstract][Full Text] [Related]
6. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
7. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Montgomery RB; Makary E; Schiffman K; Goodell V; Disis ML Cancer Res; 2005 Jan; 65(2):650-6. PubMed ID: 15695410 [TBL] [Abstract][Full Text] [Related]
8. Selection of tumor-specific internalizing human antibodies from phage libraries. Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812 [TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Vaisman N; Nissim A; Klapper LN; Tirosh B; Yarden Y; Sela M Immunol Lett; 2000 Dec; 75(1):61-7. PubMed ID: 11163868 [TBL] [Abstract][Full Text] [Related]
10. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826 [TBL] [Abstract][Full Text] [Related]
11. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958 [TBL] [Abstract][Full Text] [Related]
12. The role of erbB-2 and its ligands in growth control of malignant breast epithelium. Lupu R; Dickson RB; Lippman ME Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228 [TBL] [Abstract][Full Text] [Related]
13. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Ethier SP; Kokeny KE; Ridings JW; Dilts CA Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058 [TBL] [Abstract][Full Text] [Related]
16. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Komurasaki T; Toyoda H; Uchida D; Morimoto S Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975 [TBL] [Abstract][Full Text] [Related]
17. The ErbB/HER receptor protein-tyrosine kinases and cancer. Roskoski R Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434 [TBL] [Abstract][Full Text] [Related]
18. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890 [TBL] [Abstract][Full Text] [Related]
19. Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb/c mice. Yip YL; Smith G; Ward RL Immunol Lett; 2001 Dec; 79(3):197-202. PubMed ID: 11600198 [TBL] [Abstract][Full Text] [Related]
20. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]